Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danvatirsen in advanced cancers and lymphoma
NCT01563302Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Feb 2012
- Primary completion
- Mar 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of danvatirsen in cancer, diffuse large B-cell lymphoma (DLBCL), lymphoma, sponsored by Ionis Pharmaceuticals. Started Feb 2012; status: completed.
02
Drugs
danvatirsen
03
Conditions
cancerdiffuse large B-cell lymphoma (DLBCL)lymphoma
Beyond the preview
Go deeper on NCT01563302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01563302.